HYPATIA: A prospective randomized controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies

Summary

Women with antiphospholipid antibodies are more likely to have pregnancy complications, and antiphospholipid syndrome is a serious acquired blood clotting condition. Pregnancy complications may include recurrent or late pregnancy loss, placental problems like pre-eclampsia (high blood pressure and protein in the urine) or growth restriction (small babies), or blood clotting problems.

Low-dose aspirin and/or injectable blood thinners called low-molecular-weight heparin are used for patients with antiphospholipid antibodies or antiphospholipid syndrome to prevent recurrent pregnancy complications or blood clots. However, pregnancy complications still occur despite our best therapies of aspirin and injectable blood thinners.

The purpose of this research study is to find out whether a drug called hydroxychloroquine may help improve pregnancies in women with APS. This is a drug that is safe in pregnancy, and is used for other indications.

This study is a randomized controlled trial, which means that a participant would either receive hydroxychloroquine or a placebo drug. This would start before pregnancy, and continue during pregnancy. Follow-up would occur before pregnancy, during pregnancy, and after pregnancy.